Dermatology

The Biology of Psoriasis: The Communication Loop

At a Glance

Psoriasis is driven by an immune system 'false alarm' called the IL-23/IL-17 pathway. This loop causes skin cells to reach the surface in just 3 to 5 days instead of a month, piling up into scaly plaques. Biologic treatments work by blocking these signals to restore normal skin growth.

If you have psoriasis, your skin is behaving as if it is in a state of emergency, even though there is no actual threat. This “false alarm” is caused by a specific communication error within your immune system known as the IL-23/IL-17 pathway ^[1]^[2]. Understanding this biological mechanism can help you see why your skin looks and feels the way it does, and why modern treatments are so effective at stopping the cycle.

The Skin Cell “Pile-Up”

In healthy skin, cells are born in the deep layers and slowly move to the surface over about 28 to 30 days [NPF]. By the time they reach the surface, they are flat and ready to be shed naturally.

With psoriasis, the “alarm” causes this process to move into hyper-speed. Your skin cells now mature and reach the surface in just 3 to 5 days ^[3]^[4]. Because they are moving so fast, they don’t have time to shed. Instead, they pile up on the surface, creating the thick, scaly patches called plaques ^[5].

Your Immune System’s False Alarm

To understand why this happens, imagine your immune system as a high-tech security and fire-alarm system. In psoriasis, three main players get stuck in a “feed-forward” loop that keeps the alarm ringing.

1. The Lookouts: Dendritic Cells

Dendritic cells are like the security guards or lookouts of your immune system. Their job is to scan for invaders like bacteria or viruses ^[6]. In psoriasis, these lookouts mistakenly signal a “Code Red” by releasing a cytokine (a chemical messenger) called IL-23 ^[7].

2. The Special Forces: T-Cells

T-cells (specifically a type called Th17 cells) are the elite response team. When they receive the IL-23 message, they gear up and move into the skin ^[8]^[9]. Once there, they release their own powerful messenger called IL-17 ^[10].

3. The Reinforcements: Keratinocytes

Keratinocytes are your actual skin cells. When they “hear” the IL-17 alarm, they don’t just divide faster—they also start acting like immune cells themselves ^[11]. They release more inflammatory signals, including TNF-alpha, which travels back to the lookouts and tells them to keep sending more IL-23 ^[12].

Breaking the Cycle

This creates a self-sustaining loop: the immune system tells the skin to grow, and the growing skin tells the immune system to keep attacking ^[13].

Component	Role in Psoriasis	Analogy
Dendritic Cells	Release IL-23 to start the alarm ^[6].	The Lookout (Security)
T-Cells	Release IL-17 to target the skin ^[8].	The Response Team
Cytokines	Messengers (IL-23, IL-17, TNF-alpha) ^[5].	The Radio Signals
Keratinocytes	Skin cells that divide too fast ^[14].	The Construction Crew

Modern biologics—highly targeted medications—work by acting like “signal jammers” ^[15]. They intercept specific cytokines like IL-23 or IL-17 before they can deliver their message ^[16]. By cutting these specific “wires” in the alarm system, the skin cells can finally slow down and return to their normal 28-day cycle ^[17].

Common questions in this guide

Why do psoriasis plaques form on my skin?

Psoriasis plaques form because skin cells mature and reach the surface in just 3 to 5 days instead of the normal 28 to 30 days. Because they are moving so fast, they don't have time to shed naturally and instead pile up on the surface of your skin.

What is the IL-23/IL-17 pathway?

The IL-23/IL-17 pathway is a communication loop in your immune system that mistakenly signals a state of emergency. This false alarm involves immune cells releasing chemical messengers that tell your skin cells to multiply rapidly, driving psoriasis symptoms.

How do biologic treatments work for psoriasis?

Biologic medications act like signal jammers in your immune system. They intercept specific inflammatory messengers, such as IL-23 or IL-17, which breaks the communication loop and allows your skin cells to return to a normal growth cycle.

Can a skin injury trigger a psoriasis flare?

Yes, physical stress or injury to the skin can act as a trigger for psoriasis. This trauma can set off the rapid skin cell turnover cycle in that area, causing new plaques to develop.

Curated prompts to bring to your next appointment.

1.Based on my symptoms, does it seem like my IL-23/IL-17 pathway is particularly overactive?
2.Which specific part of this communication loop (IL-23, IL-17, or TNF-alpha) would the treatments you're recommending target?
3.If I am achieving clear skin on my current treatment, does that mean the 'feed-forward' loop has been successfully stopped?
4.Are there any tests that can show the levels of these inflammatory cytokines in my system?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (17)

1
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
Reich K, Pinter A, Lacour JP, et al.
The British journal of dermatology 2017; (177(4)):1014-1023 doi:10.1111/bjd.15666.
PMID: 28542874
2
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.
Menter A, Krueger GG, Paek SY, et al.
Dermatology and therapy 2021; (11(2)):385-400 doi:10.1007/s13555-021-00483-2.
PMID: 33512665
3
Psoriatic T cells reduce epidermal turnover time and affect cell proliferation contributed from differential gene expression.
Li J, Li X, Hou R, et al.
The Journal of dermatology 2015; (42(9)):874-80 doi:10.1111/1346-8138.12961.
PMID: 26046687
4
Transepidermal Water Loss in Psoriasis: A Case-control Study.
Nikam VN, Monteiro RC, Dandakeri S, Bhat RM
Indian dermatology online journal 2019; (10(3)):267-271 doi:10.4103/idoj.IDOJ_180_18.
PMID: 31149569
5
A review of core immuno-inflammatory mechanisms and key regulatory targets in psoriasis.
Zhou W, Li Z, Liu X, et al.
American journal of clinical and experimental immunology 2026; (15(3)):156-192 doi:10.62347/YBMA7699.
PMID: 42487722
6
Immunoregulation by DC and T cells in psoriasis with probable immunotherapeutic approaches.
Kundu S, Paul R, Chakraborty K
International reviews of immunology 2026; (45(4)):213-228 doi:10.1080/08830185.2026.2650139.
PMID: 42041098
7
Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery.
Gauld SB, Gauvin D, Olson L, et al.
Journal of dermatological science 2018; (92(1)):45-53 doi:10.1016/j.jdermsci.2018.08.001.
PMID: 30149967
8
T helper 17 cells and group 3 innate lymphoid cells define a spectrum of psoriasis endotypes.
Schön MP
Frontiers in immunology 2026; (17()):1880068 doi:10.3389/fimmu.2026.1880068.
PMID: 42465763
9
The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
Puig L, Costanzo A, Muñoz-Elías EJ, et al.
The British journal of dermatology 2022; (186(5)):773-781 doi:10.1111/bjd.20963.
PMID: 34939663
10
Anti IL-17 in psoriasis.
Ly K, Smith MP, Thibodeaux Q, et al.
Expert review of clinical immunology 2019; (15(11)):1185-1194 doi:10.1080/1744666X.2020.1679625.
PMID: 31603358
11
IL-17 Signaling in Keratinocytes Orchestrates the Defense against Staphylococcus aureus Skin Infection.
Moos S, Regen T, Wanke F, et al.
The Journal of investigative dermatology 2023; (143(7)):1257-1267.e10 doi:10.1016/j.jid.2023.01.016.
PMID: 36736996
12
Psoriasis pathogenesis and the development of novel targeted immune therapies.
Hawkes JE, Chan TC, Krueger JG
The Journal of allergy and clinical immunology 2017; (140(3)):645-653 doi:10.1016/j.jaci.2017.07.004.
PMID: 28887948
13
An Interleukin-25-Mediated Autoregulatory Circuit in Keratinocytes Plays a Pivotal Role in Psoriatic Skin Inflammation.
Xu M, Lu H, Lee YH, et al.
Immunity 2018; (48(4)):787-798.e4 doi:10.1016/j.immuni.2018.03.019.
PMID: 29653697
14
A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis.
Wu L, Chen X, Zhao J, et al.
The Journal of experimental medicine 2015; (212(10)):1571-87 doi:10.1084/jem.20150204.
PMID: 26347473
15
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
Armstrong AW, Read C
JAMA 2020; (323(19)):1945-1960 doi:10.1001/jama.2020.4006.
PMID: 32427307
16
IL-23 blockade: A strategy for managing pain-related inflammatory diseases.
García-Domínguez M
International review of cell and molecular biology 2026; (401()):225-245 doi:10.1016/bs.ircmb.2026.02.005.
PMID: 42161470
17
IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG, Wharton KA, Schlitt T, et al.
The Journal of allergy and clinical immunology 2019; (144(3)):750-763 doi:10.1016/j.jaci.2019.04.029.
PMID: 31129129

This page explains the biological mechanisms of psoriasis for educational purposes only. Always consult your dermatologist to understand your specific diagnosis and treatment options.

Get notified when new evidence is published on psoriasis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents